Average Insider

Where insiders trade, we follow

$LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Healthcare
Sector
Biotechnology
Industry
Than Powell
CEO
25
Employees
$2.51
Current Price
$12.52M
Market Cap
52W Low$2.30
Current$2.512.1% above low, 97.9% below high
52W High$12.30

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
No insider transactions found

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 12, 2026
EPS
Estimated-$1.70
Actual-$1.91
Miss
Revenue
Estimated$800.00K
Actual$115.00K
Miss
Nov 11, 2026
EPS
Estimated-$1.70
ActualN/A
Revenue
Estimated$800.00K
ActualN/A
Nov 10, 2026
EPS
Estimated-$1.70
ActualN/A
Revenue
Estimated$800.00K
ActualN/A
Nov 6, 2026
EPS
Estimated-$1.70
ActualN/A
Revenue
Estimated$800.00K
ActualN/A
Nov 3, 2026
EPS
Estimated-$1.95
ActualN/A
Revenue
Estimated$563.50K
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1